Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neridronate for Osteoporosis in Thalassemia
NCT01140321Phase 2Completed
- Sponsor
- Ospedali Galliera
- Start
- Jan 2004
- Primary completion
- May 2010
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of neridronic acid in osteoporosis (2 arms), sponsored by Ospedali Galliera. Primary endpoint: Bone Mass Density at 24 months. Started Jan 2004; status: completed.
02
Drugs
neridronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT01140321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01140321.